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Abstract 
Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) 
are limited, especially for those with progressive disease and for those who experience 
treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), 
has been approved for the treatment of patients with low- or intermediate-grade advanced 
pNET. In the randomized phase III RADIANT-3 study in patients with low- or intermediate-
grade advanced pNET, everolimus significantly increased progression-free survival (PFS) and 
decreased the relative risk for disease progression by 65% over placebo. This case report 
describes a heavily pretreated patient with high-grade pNET and liver and peritoneal 
metastases who achieved prolonged PFS, clinically relevant partial radiologic tumor response, 
and resolution of constitutional symptoms with improvement in Karnofsky performance 
status while receiving a combination of everolimus and octreotide long-acting repeatable 
(LAR). Radiologic and clinical responses were maintained for 19 months, with minimal toxicity 
over the course of treatment. This case supports the findings that the combination of 
everolimus plus octreotide LAR may be considered for use in patients with high-grade pNET 
and progressive disease. Although behavior and aggressiveness are different between low- 
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or intermediate-grade and high-grade pNET, some high-grade pNET may express mTOR; 
hence, everolimus should be considered in a clinical trial. © 2013 S. Karger AG, Basel 
Introduction 
Pancreatic neuroendocrine tumors (pNET), neoplasms that arise from cells of the endo-
crine system, represent approximately 1% of all cases of pancreatic cancer by incidence and 
9% by prevalence in the United States [1]. In the European Union, the incidence is estimated 
to be 5.25/100,000 [2]. Prognosis is generally poor because the diagnosis is frequently 
unresectable or metastatic disease. Patients with low- or intermediate-grade advanced 
disease have a median survival time of 24 months; for those with poorly differentiated (high-
grade) pNET, median survival time is even shorter (≤10 months) [1, 3]. Current clinical aims 
focus on prolonging progression-free survival (PFS) for patients with advanced pNET while 
minimizing treatment-related toxicities. 
Classic European guidelines for the management of advanced low-grade pNET recom-
mend streptozocin plus 5-fluorouracil/doxorubicin or, currently, temozolomide, with or 
without capecitabine, as chemotherapy, and everolimus or sunitinib as targeted agents. 
Although treatment with chemotherapy results in response rates of ~35%, it is associated 
with severe toxicity [2, 4–7]. Once patients experience treatment failure, therapeutic options 
are limited. 
As in patients with low-grade NET, recommendations for first-line therapy in patients 
with high-grade tumors include chemotherapy that is based on the pattern of small cell lung 
cancer with etoposide and platinum [8]. Although patients with high-grade advanced tumors 
have the highest response rates, the duration of response is often short, and there is little 
evidence of benefit beyond 4 treatment cycles [8]. Retreatment with chemotherapy after 
relapse occurring 3–6 months following the first treatment may be considered but has not 
been investigated in trials [8]. 
Everolimus, an orally administered mammalian target of rapamycin (mTOR) inhibitor, 
has demonstrated both clinical efficacy and acceptable toxicity in patients with low- or 
intermediate-grade advanced pNET [9]. Positive results from 2 phase II studies subsequently 
prompted further investigation in this patient group with the prospective, randomized, 
phase III RADIANT-3 trial [10]. RADIANT-3 was conducted to assess the efficacy and safety 
of everolimus (10 mg) compared with placebo among patients with low- or intermediate-
grade advanced pNET and radiologic documentation of disease progression [10]. Results 
showed median PFS to be significantly longer among patients receiving everolimus than 
among those receiving placebo [11.0 vs. 4.6 months; hazard ratio, 0.35; 95% confidence 
interval (CI), 0.27–0.45; p < 0.001). The objective response rate by Response Evaluation 
Criteria In Solid Tumors version 1.0 (RECIST v1.0) was also higher with everolimus than 
with placebo (all partial responses: 5 vs. 2%, respectively). Stable disease was observed in 
73% of everolimus-treated patients compared with 51% of those receiving placebo, and 
tumor shrinkage was also greater in the everolimus arm (64%) compared with the placebo 
arm (21%). Everolimus was generally well tolerated; adverse events were primarily grade 
1/2 in severity, consistent with known mTOR side effects, and generally reversible. 
Thus, although clinical trials have investigated novel treatments for NET patients expe-
riencing treatment failure and disease progression, data are limited on second and 
successive lines of treatment and are even sparser for high-grade pNET, which is usually 
excluded from clinical trials. The RADIANT-3 trial enrolled patients who had previously 
received antineoplastic therapy; 49 and 50% of the everolimus-treated population received 
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previous somatostatin analogue therapy and chemotherapy, respectively [10]. Here, we 
describe prolonged clinical response to everolimus plus octreotide long-acting repeatable 
(LAR) as treatment in a patient with high-grade advanced pNET in the late-line therapy 
setting. 
Case Report 
In June 2008, a 34-year-old woman presented with a 2-month history of epigastric and 
periumbilical pain, fatigue, anorexia, nausea, and emesis. Physical assessment showed mild 
abdominal distention with painful hepatomegaly extending to the left hypochondrium, no 
adenopathy, and normal findings on echocardiogram (left ventricular ejection fraction, 
72%). Computed tomography (CT) revealed hepatomegaly with multiple lesions (the largest 
lesion measured approximately 11.5 cm in diameter), a 5 × 7-cm mass in the tail of the 
pancreas, and a collection of subcapsular hepatic, perihepatic, and perivascular fluid. An 
analysis of tumoral tissue obtained by liver biopsy showed electron-dense granules 
containing synaptophysin and chromogranin A (CgA), high mitotic count (30/10 high-power 
fields), and high expression of Ki-67 (found in 30–40% of tumor cells) (fig. 1). Octreotide 
scintigraphy confirmed somatostatin receptor expression in the pancreatic tumor and in 
liver and peritoneal metastases. At the time of diagnosis, the patient’s Karnofsky perfor-
mance status (KPS) was 70%. 
Chemotherapy was initiated with streptozocin and 5-fluorouracil in July 2008; the pa-
tient received 3 cycles of this first-line chemotherapy. In September 2008, clinical and 
biomarker evaluation demonstrated progressive disease, and treatment was switched to 
second-line cisplatin and etoposide for 4 cycles. After disease progression, the patient began 
treatment with streptozocin and doxorubicin. After the completion of 3 cycles, however, the 
disease continued to progress rapidly, as assessed by radiologic imaging and changes in 
biomarker levels (CgA value, 4,381 ng/ml) (table 1). 
After 9 months of chemotherapy and 3 lines of therapy, the patient had a KPS of 60%, 
peritoneal metastases, and palpable hepatomegaly. She required high-dose opioids to 
achieve analgesia. Fourth-line treatment with temozolomide (150 mg/m2 on days 9–14) and 
capecitabine (1,000 mg/m2 for 14 days every 3 weeks) was subsequently initiated and led to 
the achievement of partial radiologic response at 12 weeks (4 cycles); however, the patient 
experienced disease progression after 6 cycles of therapy. 
In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was 
hospitalized because of toxicity and general deterioration in health. She had uncontrolled 
pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease 
progression that prevented her from eating without severe nausea. CgA concentration 
increased to 4,600 ng/ml, KPS decreased to 50%, and CT demonstrated massive hepatic and 
peritoneal tumor infiltration (fig. 2a). Therefore, the patient was given intravenous fluids, 
morphine, scopolamine butyl bromide, dexamethasone, and subcutaneous octreotide as 
palliative and conservative therapy. After 1 week, she was able to tolerate oral fluids and 
drugs and experienced some improvement in general state. Taking into account initial data 
findings from the recent RADIANT-2 study [11], the patient’s age, and her request to receive 
further lines of treatment, everolimus 10 mg/day plus octreotide LAR 30 mg every 4 weeks 
were initiated upon patient informed consent and compassionate use guidelines. Octreotide 
LAR had not previously been administered because of the patient’s high baseline Ki-67 index 
(30–40%). 
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Fifteen days after the initiation of sixth-line therapy with everolimus plus octreotide 
LAR, the CgA concentration decreased to 1,388 ng/ml. The patient achieved partial 
radiologic response (>50% decrease in tumor size) after 2 months of treatment (fig. 2b). By 
January 2010, her general health status had markedly improved, corresponding to a KPS of 
90%, with pain and oral restrictions alleviated. Clinically important partial response 
(decrease in tumor size >80%) was confirmed by CT (as per RECIST v1.0; fig. 2c) and by 
reduced CgA levels after 8 months of therapy with everolimus (fig. 3). The lowest CgA value, 
137 ng/ml, was achieved in August 2010 after approximately 1 year of treatment. 
Throughout the course of everolimus plus octreotide LAR treatment, the patient experi-
enced grade 1 hyperglycemia and grade 2 anemia, which were treated with an antidiabetic 
diet and erythropoietin plus intravenous iron therapy, respectively. Grade 1 stomatitis was 
also documented but did not require pharmacologic intervention. After 1 year of treatment, 
the patient reported sporadic grade 1 emesis, grade 1 diarrhea, and grade 1 hand-foot 
syndrome. 
In December 2010, after 15 months of everolimus and octreotide LAR as sixth-line 
therapy, the patient continued to be asymptomatic and had a KPS of 90%. Assessment by CT 
demonstrated an increase in the size of a peritoneal node (from 17 mm in early scans to 25 
mm). To prevent disease progression, everolimus was administered at a higher dose (15 
mg/day), and 1 month later the node had decreased in size (to 21 mm). 
After more than 1 year of treatment benefit with everolimus, during CT evaluation in 
March 2011, the patient’s liver metastases were shown to have progressed. A diagnostic 
biopsy was repeated. However, it was possible only to confirm the high Ki-67 index and 
electron-dense granules containing synaptophysin and CgA. Most of the cells were necrotic, 
and it was not possible to check for tissue expression of potential everolimus response 
predictors such as mTOR and 4EB1. One week later clinical progression was reported, and 2 
weeks later the patient was hospitalized with liver failure, fever, jaundice, painful hepato-
megaly, extrinsic compression of the stomach, anorexia, and asthenia. After progressive 
deterioration in her general health, the patient died on April 4, 2011, 33 months after the 
initial diagnosis and 19 months after the initiation of treatment with everolimus plus 
octreotide LAR. 
Discussion 
In the case presented here, a patient with high-grade pNET and 5 failed chemotherapy 
regimens was treated with everolimus plus octreotide LAR and achieved prolonged 
objective clinical and radiologic response, including improvement in hepatic and peritoneal 
metastatic sites, reduction in disease progressive biomarkers, and resolution of constitu-
tional symptoms with improved KPS. The radiologic response persisted for more than 15 
months, and CT assessment revealed the important partial radiologic response of >80% 
decrease in tumor size after 4 months of initiation of everolimus plus octreotide LAR 
therapy. The regimen was well tolerated by the patient, and adverse events (hyperglycemia, 
sporadic emesis, diarrhea, and hand-foot syndrome) were generally manageable and grade 1 
in severity. 
The combination of everolimus plus octreotide LAR demonstrated markedly improved 
clinical benefit compared with previous first- to fifth-line treatment regimens administered 
to the patient (table 1). Partial radiologic response was achieved only at 12 weeks with 
fourth-line temozolomide and capecitabine, but rapid disease progression was observed in 
<6 months with this regimen and in <3 months with other therapy lines. One explanation for 
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the efficacy of temozolomide and capecitabine is the decreased expression of the DNA repair 
enzyme O6-methylguanine-DNA methyltransferase (MGMT) in pNET. Future studies should 
investigate whether low MGMT expression in metastatic pNET is a predictive factor that 
correlates with response to capecitabine and temozolomide [12]. Treatment with everoli-
mus plus octreotide LAR, on the other hand, resulted in dramatic clinical and CT imaging 
responses and PFS of 19 months. 
The patient in this study derived a clinical benefit with everolimus-based therapy simi-
lar to the median values reported in the RADIANT trials, which enrolled patients with low-
grade NET [10]. In the phase III RADIANT-3 trial, patients with pNET receiving 10 mg 
everolimus achieved a median PFS of 11 months, and 34% of patients were progression free 
at 18 months [10]. Treatment with the same dose of everolimus plus octreotide LAR in this 
case study prolonged PFS to approximately 15–19 months, which is similar to the results 
reported in RADIANT-2 [11]. Only 4.8% of patients experienced partial response and 64% 
minor tumor shrinkage (not meeting RECIST v1.0 criteria) in RADIANT-3 [10], whereas our 
patient achieved major tumor shrinkage with everolimus plus octreotide LAR. The clinical 
and radiologic benefits were surprising considering that a poorer clinical outcome might 
have been expected given the disease stage, high-grade tumor, 5 failed chemotherapies, and 
poor KPS. 
Neither RADIANT-3 nor RADIANT-2 included objective tumor response as a secondary 
endpoint, whereas the PROMID study was a phase III trial investigating the antitumor effects 
of octreotide LAR in patients with metastatic neuroendocrine midgut tumors [13]. Median 
time to tumor progression was 14.3 months (95% CI, 11.0–28.8 months) and 6.0 months 
(95% CI, 3.7–9.4 months) in patients who received octreotide LAR and placebo, respectively 
[12]. The PROMID patient population was drug naive and excluded those with a prolonged 
(>4 weeks) history of previous therapies. The PROMID and RADIANT-2 studies included 
patients with well-differentiated midgut tumors, which are indolent [11, 13]. The estimated 
time to tumor progression for our patient was similar to that reported for patients in 
PROMID, but the tumor regression seen in our patient was better than that reported for 
those patients [12]. 
Our patient tolerated everolimus plus octreotide LAR as a sixth-line regimen for the 
management of high-grade pNET with minimal toxicity, similar to what has been reported in 
the RADIANT-3, RADIANT-2, and PROMID trials [11, 13]. Treatment strategies associated 
with reduced toxicity, as demonstrated with everolimus-based therapy, become particularly 
important in the late-line setting because health-related quality of life often outweighs 
clinical benefit in patients with reduced lifespans. 
The effect of everolimus in poorly differentiated tumors is unknown; these tumors are 
usually excluded from clinical trials because of their aggressiveness. However, these tumors 
have a better response rate to chemotherapy and may express more mTOR than well-
differentiated tumors, and mTOR elevation appears to be consistent across the primary 
tumor site [14, 15]. Although there are no published studies that confirm it, everolimus may 
be a valuable treatment option in patients with poorly differentiated NET, either before the 
initiation of chemotherapy to sensitive tumor cells or after chemotherapy to help maintain 
response over time. It should be noted that the only chemotherapy regimen with confirmed 
activity in this setting is cisplatin and etoposide. 
Treatment with everolimus plus octreotide LAR demonstrated definitive clinical re-
sponse and prolonged PFS of more than 15 months in this heavily pretreated patient with 
high-grade pNET. Despite this regimen having been a sixth-line therapy, it improved clinical 
benefit with minimal toxicity compared with the 5 other previous lines of treatment the 
patient had received. In summary, this case study suggests the combination of everolimus 
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plus octreotide LAR may offer a valuable treatment strategy for patients with heavily 
pretreated, advanced, high-grade pNET. 
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Table 1. Lines of treatment administered from June 2008 to March 2011 
    
    
Line Treatment Time to progression, 
months 
Best response 
    
    
First Streptozocin + 5-fluorouracil 02.5 Stable disease 
Second Cisplatin + etoposide 04 Minimum response 
Third Streptozocin + doxorubicin 02.5 Progressive disease 
Fourth Temozolomide + capecitabine 05 Partial response 
Fifth Paclitaxel 00 – 
Sixth Everolimus + octreotide LAR 19 Partial response 
    
    
 
 
 
 
Fig. 1. Ki-67 (left) and synaptophysin (right) staining of pNET liver biopsy. 
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Fig. 2. CT scans of the abdomen. a September 2009, after fifth-line paclitaxel. b November 2009, 2 months 
after the initiation of everolimus and octreotide LAR. c January 2010, partial response confirmed (>80% 
reduction in size per RECIST v1.0 criteria). 
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Fig. 3. CgA variation over 6 lines of therapy. CDDP = Cisplatin; DXR = doxorubicin; 5-FU = 5-fluorouracil; 
PTX = paclitaxel; SSA = somatostatin analogue; STZ = streptozocin; TMZ = temozolomide; VP-16 = 
etoposide; X = capecitabine. 
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